Terapia Génica del Cáncer
TGC
Hospital Miguel Servet
Zaragoza, EspañaPublicaciones en colaboración con investigadores/as de Hospital Miguel Servet (6)
2021
-
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)
Journal of Clinical Oncology, Vol. 39, Núm. 20, pp. 2304-2312
2019
-
Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)
British Journal of Cancer, Vol. 121, Núm. 7, pp. 537-544
-
Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study
Oncologist, Vol. 24, Núm. 1, pp. 38-46
2018
-
Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across Spain
Psycho-Oncology, Vol. 27, Núm. 6, pp. 1530-1537
2017
-
Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: A Spanish multicenter experience
Future Oncology, Vol. 13, Núm. 7, pp. 615-624
-
Laparoscopy may decrease morbidity and length of stay after elective colon cancer resection, especially in frail patients: results from an observational real-life study
Surgical Endoscopy, Vol. 31, Núm. 12, pp. 5032-5042